NCT03682952

Brief Summary

To evaluation of nailfold microcirculation in patients with chronic renal failure and its intervention therapy

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Feb 2018

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2018

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

September 12, 2018

Completed
13 days until next milestone

First Posted

Study publicly available on registry

September 25, 2018

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2019

Completed
Last Updated

September 26, 2018

Status Verified

June 1, 2018

Enrollment Period

1.2 years

First QC Date

September 12, 2018

Last Update Submit

September 25, 2018

Conditions

Keywords

Chronic Renal DiseaseNail fold microcirculationInterventional therapy

Outcome Measures

Primary Outcomes (3)

  • Nailfold microcirculation morphological integral

    Nail fold capillary microscopy examination

    Up to three and a half months

  • Nailfold microcirculation blood flow integral

    Nail fold capillary microscopy examination

    Up to three and a half months

  • Nail fold microcirculation perivascular loop integral

    Nail fold capillary microscopy examination

    Up to three and a half months

Secondary Outcomes (7)

  • The content of blood serum creatinine

    Up to three and a half months

  • The content of blood urea nitrogen

    Up to three and a half months

  • The content of blood cystatin C

    Up to three and a half months

  • eGFR

    Up to three and a half months

  • The content of blood albumin

    Up to three and a half months

  • +2 more secondary outcomes

Study Arms (3)

Experimental group

EXPERIMENTAL

Alprostadil and Beraprost sodium tablets are used to improve the microcirculation of CKD patients.

Drug: Alprostadil InjectionDrug: Beraprost sodium tablets

Anemia control group

NO INTERVENTION

Anemia patients

Control group

NO INTERVENTION

Healthy person

Interventions

Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks.

Experimental group

Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks ,then they take beraprost sodium tablets 40ug orally three times perday for 3 months.

Experimental group

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • CKD patients
  • Without dialysis
  • Blood pressure ≤ 140/90mmHg

You may not qualify if:

  • Polycystic kidney
  • Endocrine system disease
  • Cardio-cerebrovascular disease
  • Rheumatic immune disease
  • Peripheral vascular disease
  • Hematological diseases
  • Respiratory disease
  • Infection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, 221000, China

Location

Related Publications (7)

  • Leunissen KM, van den Berg BW, Cheriex EC, Slaaf DW, Reneman RS, van Hooff JP. Influence of fluid removal during haemodialysis on macro- and skin microcirculation. Haemodynamic pathophysiologic study of fluid removal during haemodialysis. Nephron. 1990;54(2):162-8. doi: 10.1159/000185838.

    PMID: 2314527BACKGROUND
  • Yuksel S, Pancar Yuksel E, Yenercag M, Soylu K, Zengin H, Gulel O, Meric M, Aydin F, Senturk N, Sahin M. Abnormal nail fold capillaroscopic findings in patients with coronary slow flow phenomenon. Int J Clin Exp Med. 2014 Apr 15;7(4):1052-8. eCollection 2014.

    PMID: 24955181BACKGROUND
  • Senet P, Fichel F, Baudot N, Gaitz JP, Tribout L, Frances C. [Nail-fold capillaroscopy in dermatology]. Ann Dermatol Venereol. 2014 Jun-Jul;141(6-7):429-37. doi: 10.1016/j.annder.2014.04.120. Epub 2014 Jun 2. French.

    PMID: 24951141BACKGROUND
  • Yuan SY. [Nail-fold microcirculatory flow in liver cirrhosis: diabetes mellitus and systemic lupus erythematosus]. Zhonghua Yi Xue Za Zhi. 1986 Aug;66(8):473-5, 512. No abstract available. Chinese.

    PMID: 3096534BACKGROUND
  • Paparde A, Neringa-Martinsone K, Plakane L, Aivars JI. Nail fold capillary diameter changes in acute systemic hypoxia. Microvasc Res. 2014 May;93:30-3. doi: 10.1016/j.mvr.2014.02.013. Epub 2014 Mar 6.

    PMID: 24607833BACKGROUND
  • Schumann L, Korten G, Holdt B, Holtz M. Microcirculation of the fingernail fold in CAPD patients: preliminary observations. Perit Dial Int. 1996 Jul-Aug;16(4):412-6.

    PMID: 8863336BACKGROUND
  • Hasegawa K, Pereira BP, Pho RW. The microvasculature of the nail bed, nail matrix, and nail fold of a normal human fingertip. J Hand Surg Am. 2001 Mar;26(2):283-90. doi: 10.1053/jhsu.2001.21519.

    PMID: 11279575BACKGROUND

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Interventions

Alprostadilberaprost

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Prostaglandins EProstaglandinsEicosanoidsFatty Acids, UnsaturatedFatty AcidsLipidsFatty Acids, MonounsaturatedAutacoidsInflammation MediatorsBiological Factors

Study Officials

  • Dong Sun, MD

    The Affiliated Hospital of Xuzhou Medical University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 12, 2018

First Posted

September 25, 2018

Study Start

February 1, 2018

Primary Completion

April 30, 2019

Study Completion

April 30, 2019

Last Updated

September 26, 2018

Record last verified: 2018-06

Data Sharing

IPD Sharing
Will not share

Locations